James Coffin, PhD also known as Jamie, is a pioneer in the healthcare and life sciences sector. As President and Chief Operating Officer at Sema4, he is responsible for business development and growth, sales, client services, and lab operations.
Before joining Sema4, Jamie served as Chief Executive Officer and President at Source Medical Solutions, the leading provider of practice management and EMR solutions in the ambulatory surgical space. Previously, Jamie was Worldwide Vice President and General Manager at Dell, leading the Global Healthcare Life Science business over a six-year period to become the premier healthcare IT services company in the world with $3.5 billion in revenue, and a workforce of approximately 13,000 people. He pioneered Dell’s efforts to apply leading-edge information technology into areas including EMR, data analytics, high performance and cloud computing, personalized medicine, claims processing, medical imaging, and pharmaceutical and biotech drug discovery.
Prior to Dell, Jamie served as Worldwide Vice President of IBM Healthcare and Life Sciences and grew the division to a $6.5 billion business. He was also a Director at Terascala, a company that accelerated big data applications.
Jamie earned his PhD from the University of Arkansas and his BS in Chemistry from Louisiana Tech University.
How do I contact James Coffin?
Has James Coffin been buying or selling shares of GeneDx?
James Coffin has not been actively trading shares of GeneDx over the course of the past ninety days. Most recently, James Coffin sold 174 shares of the business's stock in a transaction on Monday, October 25th. The shares were sold at an average price of $248.82, for a transaction totalling $43,294.68. Learn More on James Coffin's trading history.
Who are GeneDx's active insiders?
Are insiders buying or selling shares of GeneDx?
In the last year, GeneDx insiders bought shares 5 times. They purchased a total of 215,804 shares worth more than $4,121,270.44. In the last year, insiders at the sold shares 45 times. They sold a total of 1,902,894 shares worth more than $108,025,448.74. The most recent insider tranaction occured on December, 16th when CEO Katherine Stueland sold 10,501 shares worth more than $805,951.75. Insiders at GeneDx own 27.3% of the company.
Learn More about insider trades at GeneDx. Information on this page was last updated on 12/16/2024.
